In Down syndrome (DS), the overall genetic imbalance caused by trisomy of chromosome 21 leads to a 34 complex pleiotropic phenotype that involves a recognizable set of facial traits. Several studies have 35
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The face, despite being a variable phenotype with high levels of plasticity and remodeling throughout 50 differences between WT and TS mice. Finally, to confirm that the patterns revealed by the EDMA 129 analyses were not due to random chance alone, we tested the statistical significance of the results 130 performing simulation tests. We performed a subsampling approach in which we generated random 131 pseudo-subsamples with increasing number of DS treated cases, and for each simulation we 132 recomputed all the EDMA analyses and estimated the associated FIS scores (see Materials & Methods 133 for further details). 134
The histograms in Fig. 2 compare the distribution of randomly generated FIS scores with the FIS 135 obtained using the experimental data. Although the tests did not reach statistical significance because of 136 large degrees of variation, the results of the simulation analyses tended to confirm our previous results: 137 a negative effect of the high EGCG dose, but a positive effect of the low dose. The high dose EGCG 138 treatment was associated with a negative FIS, as the number of facial differences between WT and TS 139 mice increased when more TS treated mice were included in the simulated groups, and thus suggesting 140 a detrimental effect of the high dose EGCG treatment (Fig. 2) . On the contrary, the low dose EGCG 141 treatment was associated with a positive FIS (Fig. 2) , as the number of facial differences decreased with 142 increasing number of TS treated mice, suggesting a normalization of the facial phenotype at low EGCG 143
doses. 144 145
Effect of EGCG treatment on facial shape of children with DS 146
The findings based on the experimental DS mouse models led us to explore whether EGCC treatment 147 can also modulate facial development in humans. To this aim, and given that some parents are 148 administering over-the-counter green tea extracts to their children because these are commercially 149 available as dietary supplements, we were able to perform the first observational study ever to 150 investigate whether EGCG treatment improves facial dysmorphology in children with DS. Our 151 investigation is a cross-sectional study, on a cohort of individuals with DS that started green tea 152 consumption on the initiative of their parents encouraged by the pro-cognitive effects of EGCG in DS. 153
The participants in our study did not follow a systematic EGCG usage pattern, and thus had not 154 homogeneous or standardized dosage, onset, and duration of treatment. Yet, assessing whether there is 155 an effect of EGCG treatment on DS facial development may provide valuable evidence to determine 156 whether EGCG treatment can alleviate facial dysmorphologies in DS. 157
To assess the effect of EGCG supplementation on facial development of children with DS, we first 158 acquired 3D facial images of children with DS, children with DS that have received EGCG treatment, 159 mosaic cases with quantified percentages of trisomic cells (50-80%), and euploid individuals (see Table  160 6 S1_3 for sample composition and Table SI_4 for cohort and EGCG treatment details). Individuals were 161 categorized into three age groups (0-3 yrs., 4-12 yrs., 13-18 yrs.) to determine whether EGCG treatment 162 could have differing effects depending of the stage of development and onset of the treatment. Hence, 163 facial shape was evaluated within each age group using multivariate geometric morphometric methods. 164
We first assessed the overall face shape differences between euploid children and children with DS, with 165 particular focus on children with DS that had received EGCG supplementation. Our results, based on 166
Procrustes analyses of a configuration of 21 landmarks located throughout the face (Fig. SI_1) , showed 167 almost complete separation between euploid children and those with Ts21 in all three age groups (Fig.  168 3), with slight to moderate overlap depending on the specific age range. Overall, facial phenotypes 169 associated with DS included flat and wider faces, oblique palpebral fissures, flat nasal bridges, wider 170 noses, and thicker lips. Facial phenotypes associated with the euploid condition presented slender and 171 slightly convex faces, with horizontal palpebral fissures, narrow noses and thin lips. The position in the 172 morphospace of the DS cases treated with EGCG varied greatly in the different age groups. Depending 173 on the age of initiation of the treatment, DS cases treated with EGCG showed facial phenotypes that fell 174 within the ranges of variation of either the DS or the euploid groups (Fig. 3) . 175
In the age group including teenagers from 13 to 18 years old, the participants that had taken the EGCG 176 treatment completely overlapped with other individuals with DS that never received a treatment. Thus, 177 the facial shapes of teenagers with DS were similar regardless of the EGCG treatment, suggesting that 178 EGCG did not have any effect on facial shape when the treatment started late in adolescence (Fig. 3a) . 179
In the age group from 4 to 12 years old, the two DS treated cases fell in an intermediate morphospace 180
position, one within the euploid range of variation and the other within the overlapping area between 181 the euploid and the DS range of variation. This result showed a tendency of the children with DS treated 182 with EGCG to display milder facial phenotypes. The child receiving the lower dose fell closer to the 183 euploids, but no conclusive evidence can be drawn from these results due to the small sample size and 184 the substantial differences in the dosage/length of EGCG treatment (Fig. 3b) . 185
Finally, in the age group of youngest children (from 0 to 3 years old), we observed the most prominent 186 effect of EGCG treatment: most children with DS who had taken EGCG since early in development 187 presented a moderate facial phenotype ( When assessing facial differences in the 13-18 year age group, our results indicated only a small 209 reduction in the number of significant linear distances. A total of 61% of linear measures significantly 210 differed between the baseline comparison of DS and euploid samples (Fig. 4a) , while 53% were still 211 significantly different between euploid and treated samples (Fig. 4b) . When comparing untreated 212 children with DS and those treated with EGCG, only a minimal number of significant differences were 213 found (5%), indicating overall similarity between untreated and treated children with DS (Fig. 4c, d) . 214
A similar pattern was detected in the 4-12 year age group. EGCG treatment did not produce a 215 substantial change in the number of facial differences between euploid and trisomic children. The 216 baseline comparison of DS and euploid cases estimated that 59% of facial measurements were 217 significantly different in this age-range (Fig. 4e) , and this percentage was only reduced to 46% when 218 comparing EGCG treated individuals with DS to the euploid sample (Fig. 4f) . However, we detected that 219 the number of significant shape differences between treated and untreated children with DS was larger 220 in the 4-12 age group ( Fig. 4g ) than in the 13-18 age group (Fig. 4c ). This result could be suggesting an 221 incipient positive effect of the EGCG treatment that was however not sufficient to rescue the facial 222 phenotype entirely (Fig. 4g, h) . 223 8 Finally, the analysis of the youngest age group of 0-3 year olds revealed the most significant effect. The 224 EDMA comparison between euploid and DS children showed that 57% of linear distances were 225 significantly different (Fig. 4i) . However, only 25% of linear distances remained significant when young 226 children with DS treated with EGCG were compared to the euploid sample (Fig. 4j) . This indicated an 227 overall improvement of more than 50% of total facial measurements relative to the baseline 228 comparison. A significantly large beneficial EGCG treatment effect is thus suggested, especially on those 229 facial traits that appear as significantly different when comparing EGCG treated and untreated children 230 with DS (Fig. 4k, l) . The local EDMA morphological assessments indicated that various dimensions of the 231 nose, philtrum, cheeks and midface were improved after EGCG treatment, with the strongest effect 232 occurring in the age group of 0-3 year olds, but with less of an effect in older age groups. 233
To verify the results suggesting that EGCG improved facial development in young individuals with DS, 234 summary scores of facial improvement (FISs) were estimated and tested using the random simulation 235 approach. The FIS score quantified whether EGCG treatment decreased or increased the number of 236 shape differences identified by the EDMA between children with DS and euploid children. Results 237
showed that in older children (from 13 to 18 and from 4 to 12 years old), the FIS score was positive but 238 low, indicating only a minor relative improvement of facial shape ( Our analyses using Ts65Dn mouse model (Fig. 1) suggested that administration of EGCG at low doses 260 from E9 to P29 improved facial dysmorphology. However, the same treatment at high dose produced 261 disparate facial morphology changes with an extremely wide and abnormal range of variation (Figs. 1  262 and 2). Since some mice receiving the high EGCG dose had relatively normal facial morphology, while 263 others exhibited different and unique dysmorphology (Fig. 1) , the bimodal distribution of these results 264 may be suggestive of a threshold effect of EGCG that alters developmental canalization and reaction 265 norms by shifting craniofacial development to a different developmental pathway with a separate 266 phenotypic fate 27 . The unpredictable facial morphologies resulting from high EGCG doses, affecting both 267 wild type and trisomic mice, require further investigation to confirm the potential therapeutic window 268 of EGCG to prevent and alleviate facial dysmorphologies associated with DS. with the effect observed in humans, where the combined intervention of EGCG treatment and cognitive 276 training seemed to ameliorate memory and executive deficits in young adults with DS after taking oral 277 doses of 9 mg/kg/day of EGCG for 3-12 months 13, 16 . However, Ts65Dn mice treated with ~10, ~20, or 278 ~50mg/kg/day of EGCG starting at P24 for 3-or 7-weeks failed to show cognitive improvements 28 . 279
Regarding the effect of EGCG on skeletal traits, a recent study indicated that EGCG treatment of 200 280 mg/kg/day on gestational days 7 and 8 of pregnant Ts65Dn DS mouse models rescued some cranial vault 281 morphologies measured two months later in 6-week old offspring 17 . Research on limb long bones has 282
shown that specific conditions of EGCG treatment can lead to correction of skeletal deficits associated 283 with DS. For instance, when 3 week old Ts65Dn mice were treated with ~9 mg/kg/day of EGCG for 3 284 weeks beginning in early adolescence, they exhibited increased femoral bone mineral density relative to 285 untreated trisomic mice and trabecular microarchitecture (i.e., percent trabecular bone volume, 286 trabecular number and thickness) was rescued to euploid levels 15 . However, Ts65Dn mice treated with 287 10 ~50mg/kg/day for 7 weeks starting at P24 exhibited detrimental effects on femoral bone structure and 288 mechanical properties, such as reductions in cortical area and thickness, structural strength (yield force), 289 stiffness, and ultimate force 19 . Further experimentation with mouse models is thus critical to explain the 290 discordant effects of different conditions of EGCG treatment. 291
292
Potential of EGCG for facial bone remodeling 293
In the observational study in humans, our morphometric assessment of facial shape revealed the 294 strongest and most beneficial effect for EGCG in the youngest human age group, 0-3 years, when most 295 craniofacial growth occurs (Fig. 4) . Only younger children with DS treated with EGCG since their first 296 months of life up to 3 years presented with facial phenotypes that fell close to or within the euploid 297 range of variation (Fig. 3c) . It is during these first years of life when the skull and the face exhibit high 298 growth velocities associated with relatively large size and shape change 29 , likely driven by rapid brain 299 expansion and masticatory changes as offspring are weaned to semi-solid and solid foods. After facial 300 shape maturation is reached by 15-16 years of age 29 , facial shape is maintained fairly constant and bone 301 remodeling only occurs at a lower rate. This period coincides with our oldest age group (13 to 18 years), 302 in which no effect of the EGCG treatment was observed, probably because faces have already attained 303 their final size and shape (Figs. 3a, 4a-d ) and facial plasticity is minimal. 304
Since soft-tissues of the face are built upon the bony scaffold of the skull 30 , and because we found soft-305 tissue morphology improvement in humans and facial skeleton improvement in mouse models using a 306 low dose of EGCG, we suspect that EGCG has a potential bone-remodeling effect during early 307 development and subsequent growth. It has been previously shown that EGCG supplementation can 308 normalize many skeletal deficits. EGCG is known to modulate bone metabolism 31 , bone formation 32,33 , 309 and bone resorption 34 , potentially by hindering osteoclastogenesis 34 and inducing osteoblast 310 differentiation [35] [36] [37] [38] [39] . However, as we found in our experimental analyses on the effect of EGCG on facial 311 shape ( Figs. 1 and 2) , the specific effects greatly depend on the dosage: high doses of EGCG may 312 suppress bone formation and exacerbate skeletal defects, whereas moderate doses of EGCG may 313 enhance bone formation and attenuate birth defects 40, 41 . 314
We hypothesize that the distinctive faces associated with DS may result from poor craniofacial growth. 315
As individuals with DS show overall impairment of growth and bone formation, displaying shortened 316 limbs, low bone mineral content and density, reduced bone strength 42 and remodeling 43 , as well as 317 osteopenia and osteoporosis that worsens with age 44 , deficiencies in remodeling and relocation of 318 craniofacial bones as the face grows during the first years of development 45 may explain the typical 319 facial traits associated with DS. Increased bone resorption, reduced bone deposition, and/or lack of 320 proper relocation may cause midfacial hypoplasia and the altered shape and position of the maxilla, the 321 mandible, and nasal and orbital cavities, which are the bones with higher predisposition to resorption 45 322 and are indeed the most affected by Ts21. 323
Despite all the caveats of an observational study based on a limited sample size, including children from 324 different ages, sexes, and geographic regions and the fact that they did not received the same doses of 325 EGCG or had the same length of treatment, the simulation tests consistently detected a signal indicating 326 that EGCG treatment since early in development is associated with intermediate facial phenotypes and 327 significant facial improvement scores (FISs) (Fig. 5) . The findings of our observational study underline the 328 need to reassess the effects of EGCG on facial morphology in a clinical trial, to statistically assess and 329 control the different sources of morphological variation in larger samples of individuals following a 330 systematic treatment. 331 332
Modulating a multisystem circuit to minimize developmental alterations in DS 333
The pleiotropic effects of EGCG are likely mediated by a complex regulatory circuit controlling neural, 334 facial, cardiac and skeletal development. EGCG likely inhibits the activity of several kinases across 335 different organism tissues 19, 46 , including DYRK1A, a protein that is encoded by one of the genes that has 336 emerged to play a critical role in DS. DYRK1A is expressed in a gene-dosage dependent manner within a 337 critical region of chromosome 21, and both under-or overexpression of DYRK1A lead to neural 338 dysfunction 21 as well as to brain, craniofacial and skeletal dysmorphologies 17 . The available evidence 339 suggests that DYRK1A participates in a regulatory circuit of neural, skeletal, as well as cardiac 340 development, probably mediated through varying control of the Nuclear factor of activated T-cells 341 (NFAT) signaling pathway, a critical regulator of vertebrate development and organogenesis 24 . 342
The whole circuit is clearly altered in DS by the 1.5-fold increase in gene dosage due to Ts21. Although 343 all the genes and signaling pathways participating in this circuit are yet to be discovered, research on 344 DYRK1A has led to the discovery that a multitude of DS phenotypes can be modulated through inhibition 345 of kinase activity by EGCG. However, the potential rescuing effect of EGCG treatment on multiple 346 systems depends on several factors, such as dosage, onset and duration of the treatment, as well as 347 method of delivery and composition of EGCG-containing supplements. Hence, additional research is 348 needed to pinpoint the optimal dose and time window for EGCG administration, minimizing possible 349 detrimental and side effects, and maximizing benefits to cognitive function and biological growth, Treatment. In the first experiment, mice were treated with a high dose of EGCG (30 mg/kg/day), and in 381 the second experiment they received a lower dose (9 mg/kg/day). Since EGCG crosses the placenta and 382 reaches the embryo 48 , the treatment was administered prenatally at embryonic day 9 (E9) to optimize 383 13 treatment efficiency. We chose this time point because this is when the face starts developing and 384
Dyrk1A begins to be expressed in mouse embryos. EGCG treatment continued over the duration of the 385 experiment, from E9 until adulthood at P29. During gestation and lactation, EGCG was delivered to dams 386 dissolved in water at a concentration of 0.326 mg/L in the high dose experiment and 0.09 mg/L in the 387 low dose experiment. After weaning at postnatal day 21 and until postnatal day 29, EGCG dissolved in 388 water at the same concentrations was made available to young mice that drank ad libitum. The EGCG 389 solution was prepared freshly from a green tea extract [Mega Green Tea Extract, Life Extension, USA; 390 EGCG content of 326.25 mg per capsule] every 3 days. The dosage received was thus approximately 30 391 mg/kg/day in the high dose experiment, and 9 mg/kg/day in the low dose experiment for an adult 392 mouse, taking into account that, on average, mice weigh 20 g and drink 2 ml of water per day. 393 394 Morphometric craniofacial study. We used a total of 55 mice from eight litters. We administered EGCG 395 prenatal treatment to 50% of pregnant dams, chosen randomly, to produce approximately the same 396 number of EGCG treated and non-treated mice. Mice were genotyped by quantitative PCR from ear snip 397 samples and were distributed in four groups according to their genotype and treatment: Euploid (WT), 398
Euploid treated with EGCG (WT+EGCG), trisomic Ts65Dn (TS) and trisomic Ts65Dn treated with EGCG 399 (TS+EGCG). See Table SI_1 for details on sample composition. 400
We acquired whole-body micro computed tomography scans of the mice at postnatal day 29 using a 401 dedicated fast low-dose in vivo µCT scanner (SkyScan 1278, Bruker Micro-CT, Kontich, Belgium) at high 402 resolution (50 μm isotropic). Free-breathing mice were scanned under isoflurane anesthesia (~1-2% in 403 oxygen), while physiological functions were constantly monitored and maintained via a feedback loop 404 (temperature, breathing, visual inspection via camera). Scans were reconstructed using the software 405 NRecon v1.6.10.4, whereas skull visualization and landmarking were performed by a single observer 406 using the Amira 6.3 software (Visualization Sciences Group, FEI). Measurement error was within the 407 range of previous studies 49 . We recorded the three-dimensional coordinates of a set of 12 facial 408 anatomical landmarks (Fig. SI_1 and Table SI_2 ), to capture the shape differences between WT and TS 409 mice and to assess whether the EGCG treatment has an effect on facial development. (Table SI_3 and SI_4). To 415 % significant distances DS vs EU % significant distances DS EGCG vs EU % significant distances DS vs EU 100 480
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To verify the statistical validity of the patterns revealed by the EDMA analyses, we ran simulation tests. 482
We performed a subsampling approach in which we generated random pseudo-subsamples with 483 increasing number of DS treated cases. For each age group, the whole sample was randomly divided into 484 for each age group. Specifically, the circles in the Venn diagrams indicate the number of unique 659 significant differences DS vs EU (left), the number of common significant differences in DS+EGCG and DS 660 (intersection), and the number of unique significant differences DS+EGCG vs EU (right). 661 
